KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -15.07% | -7.66% | -- |
| Total Depreciation and Amortization | -- | -- | -3.45% | 13.97% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 16,095.16% | -99.38% | -- |
| Change in Net Operating Assets | -- | -- | -140.72% | 106.31% | -- |
| Cash from Operations | -- | -- | -35.03% | -23.51% | 17.56% |
| Capital Expenditure | -- | -- | -3.20% | -1,070.83% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 807.29% | -135.67% | -- |
| Cash from Investing | -- | -- | 738.85% | -139.07% | -82.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -30.29% | -96.73% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 680.11% | -97.05% | -- |
| Cash from Financing | -- | -- | 398.18% | -96.93% | 51,348.47% |
| Foreign Exchange rate Adjustments | -- | -- | -19.05% | 369.34% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 79.51% | -128.23% | 1,198.26% |